Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.

No abstract is available for this paper.

• Publication year

  1975

• Venue

  Biochimica et Biophysica Acta

• Publication date

  1975-05-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0005-2795(75)90216-0PMID 124594
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The behavior of isotope labelled blood proteins in thrombosis.

  1974cited by this paper
• Rate of activation and electrophoretic mobility of unmodified and partially degraded plasminogen. Effects of 6-aminohexanoic acid and related compounds.

  1974cited by this paper
• Substrate Composition and the Effect of ε-Aminocaproic Acid on Tissue Plasminogen Activator and Urokinase-induced Fibrinolysis

  1974cited by this paper
• Reversible and Irreversible Alterations of Human Plasminogen Indicated by Changes in Susceptibility to Plasminogen Activators and in Response to ∈-Aminocaproic Acid

  1974cited by this paper
• Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid.

  1974cited by this paper
• Conversion of NH2-terminal glutamic acid to NH2-terminal lysine human plasminogen by plasmin

  1973cited by this paper
• Release of an N-terminal peptide from human plasminogen during activation with urokinase.

  1973cited by this paper
• Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound.

  1973cited by this paper
• Molecular forms of plasmin and protease inhibitors in human fibrinolytic post-mortem plasma.

  1972cited by this paper
• Assay of human plasminogen in plasma by affinity chromatography.

  1972cited by this paper
• Measurement of the binding of antifibrinolytic amino acids to various plasminogens.

  1972cited by this paper
• Agarose gel electrophoresis.

  1972cited by this paper
• Differences in the Binding to Fibrin of Urokinase and Tissue Plasminogen Activator

  1972cited by this paper
• Plasminogen-Fibrinogen Complex Formation as a Prelude to Fibrinogenolysis

  1971cited by this paper
• Fibrinogenolysis and Fibrinolysis with Tissue Plasminogen Activator, Urokinase, Streptokinase-Activated Human Globulin, and Plasmin 1

  1971cited by this paper
• Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations.

  1970cited by this paper
• On the heterogeneity of activity by various types of plasmins and the spectra of inhibition of some plasmin inhibitors.

  1970cited by this paper
• Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor.

  1970cited by this paper
• Plasminogen: Purification from Human Plasma by Affinity Chromatography

  1970cited by this paper
• Radioimmunoassay of human plasminogen and plasmin.

  1969cited by this paper
• Isolation and purification of a tissue plasminogen activator and its comparison with urokinase.

  1969cited by this paper
• Biphasic Inhibition of Urokinase-Induced Fibrinolysis by ∊-Aminocaproic Acid; Distinction from Tissue Plasminogen Activator∗

  1969cited by this paper
• The plasmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate.

  1968cited by this paper
• Occlusion of Plasma Proteins by Human Fibrin: Studies using Trace‐Labelled Proteins

  1968cited by this paper
• The hydrolysis of alpha-N-acetylglycyl-l-lysine methyl ester by urokinase.

  1967cited by this paper
• Determination of Plasminogen in Clots and Thrombi

  1966cited by this paper
• The Plasminogen Content of Thrombi

  1966cited by this paper
• Ester Hydrolysis by Urokinase

  1965cited by this paper
• Plasminogen Activity of Plasma and Serum

  1962cited by this paper
• The mechanism of clot dissolution by plasmin.

  1959cited by this paper
• Factors influencing susceptibility of fibrin and fibrinogen to proteolysis by fibrinolysin.

  1957cited by this paper
• Fibrinolysis in the organism.

  1956cited by this paper
• Analytical Review: Fibrinolysis in the Organism

  1956cited by this paper
• Formation and properties of the activator of plasminogen and of human and bovine plasmin.

  1955cited by this paper
• The action of plasmin on fibrin and fibrinogen in blood.

  1953cited by this paper
• The Action of Plasmin on Fibrin and Fibrinogen in Blood.1

  1953cited by this paper
• Partial purification and properties of a proteolytic enzyme of human serum.

  1949cited by this paper

• Tranexamic Acid in Dacryocystorhinostomy: A Systematic Review

  2026cites this paper
• Neuronal conversion of single-chain tissue-type plasminogen activator into its two-chain form: implications in neurodevelopment, learning, and memory

  2025cites this paper
• The use of tranexamic acid in prophylaxis of postpartum haemorrhage

  2025cites this paper
• Pharmacokinetics of aminocaproic acid in thoroughbred horses.

  2023cites this paper
• Postpartum Hemorrhage and Tranexamic Acid: A Literature Review

  2023cites this paper
• The effect of tranexamic acid on blood loss after vaginal delivery and caesarian section

  2023cites this paper
• Comparative study of topical and intravenous tranexamic acid for prevention of postpartum haemorrhage in placenta praevia cesarean section

  2021cites this paper
• Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence‐based review

  2018cites this paper
• The impact of tranexamic acid on blood loss during caesarean section and vaginal birth

  2018cites this paper
• Administration of tranexamic acid to patients undergoing surgery for adolescent idiopathic scoliosis evokes pain and increases the infusion rate of remifentanil during the surgery

  2017cites this paper
• The influence of thermal trauma on pro- and anticoagulant activity of erythrocyte-derived microvesicles.

  2016cites this paper
• Antifibrinolytic therapy to reduce haemoptysis from any cause.

  2016cites this paper
• Tranexamic acid–associated seizures: Causes and treatment

  2015cites this paper
• Tranexamic Acid Modulation of Excitatory and Inhibitory Amino Acid Receptors: A Potential Mechanism for Postoperative Seizures

  2015influential citation
• Epistaxis complicated by rivaroxaban managed with topical tranexamic acid.

  2015cites this paper
• Tranexamic acid evokes pain by modulating neuronal excitability in the spinal dorsal horn

  2015cites this paper
• Efficacy of tranexamic acid in reducing blood loss during lower segment caesarean section

  2014cites this paper
• Effect of Tranexamic acid (TEA) on Blood Loss in Total Knee Arthroplasty (TKA)

  2013cites this paper
• A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.

  2013cites this paper
• Antifibrinolytic therapy to reduce haemoptysis from any cause.

  2012cites this paper
• Reducing Heavy Menstrual Bleeding: Safety and Efficacy of Tranexamic Acid:

  2012cites this paper
• Tranexamic Acid

  2012cites this paper
• fibrins: its significance in hemostatic defect in factor XIII deficiency Differential binding of plasminogen to crosslinked and noncrosslinked

  2011cites this paper
• Tranexamic acid therapy for heavy menstrual bleeding

  2011cites this paper
• following thrombin stimulation Histidine-rich glycoprotein is present in human platelets and is released

  2011cites this paper
• Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes.

  2010cites this paper
• Plasminogen on the surfaces of fibrin clots prevents adhesion of leukocytes and platelets

  2010cites this paper
• Effects of intravenous aminocaproic acid on exercise-induced pulmonary haemorrhage (EIPH).

  2010cites this paper
• The fibrinolytic system.

  2009cites this paper
• Activation of factor XII in plasma from rats pretreated with tranexamic acid. Inhibition of a plasmin-induced loss of the functional activity of high molecular weight kininogen.

  2009cites this paper
• [Thrombolytic treatment of venous thrombi with combined use of streptokinase and human plasminogen (author's transl)].

  2008cites this paper
• A partially degraded form of human plasminogen in circulating blood.

  2008cites this paper
• [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].

  2007cites this paper
• Antifibrinolíticos e Cirurgia Cardíaca com Circulação Extracorpórea* Antifibrinolytics and Cardiac Surgery with Cardiopulmonary Bypass

  2007cites this paper
• Tratamiento de las epistaxis en la telangiectasia hemorrágica hereditaria (enfermedad de Rendu-Osler-Weber) con ácido tranexámico

  2007cites this paper
• Pharmacokinetics and pharmacodynamics of ε-aminocaproic acid in horses

  2007cites this paper
• Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells

  2007cites this paper
• Pharmacokinetics and pharmacodynamics of epsilon-aminocaproic acid in horses.

  2007cites this paper
• [Antifibrinolytics and cardiac surgery with cardiopulmonary bypass.].

  2007cites this paper
• The Role of Histidine-rich Glycoprotein in Coagulation & Fibrinolysis

  2007cites this paper
• States in a Patient With Congenital Deficiency of a 2-Plasmin Inhibitor

  2005cites this paper
• Histidine‐rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems

  2005cites this paper
• Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin‐induced cell detachment and apoptosis

  2005cites this paper
• The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen activator, urokinase, and coagulation factor XII

  2005cites this paper
• Bleeding in cardiac surgery: its prevention and treatment--an evidence-based review.

  2005cites this paper
• Untersuchungen zur Struktur und Funktion der Plasminogen-bindenden alpha-Enolase aus Streptococcus pneumoniae und der Tubulin-Tyrosin Ligase aus Sus scrofa

  2004cites this paper
• Release of fibrinolytic activators from the cornea and conjunctiva

  2004cites this paper
• Fibrin structures during tissue-type plasminogen activator-mediated fibrinolysis studied by laser light scattering: relation to fibrin enhancement of plasminogen activation

  2004cites this paper
• Protease inhibitors in the treatment of hereditary angioedema.

  2003cites this paper
• The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation.

  2002cites this paper
• In vivo regulation of plasminogen function by plasma carboxypeptidase B.

  2002cites this paper
• High Dose of Tranexamic Acid for Treatment of Severe Menorrhagia in Patients with von Willebrand Disease

  2002cites this paper
• Diffusional transport of urokinase and acyl-urokinase into fibrin and plasma clots: time of contact and fibrinolytic response in vitro

  2001cites this paper
• Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein.

  2001cites this paper
• More porous fibrin gel structure obtained by interaction with Lys-plasminogen than with Glu-plasminogen

  2000cites this paper
• Synthetic antifibrinolytics are not associated with an increased incidence of baffle fenestration closure after the modified Fontan procedure.

  2000cites this paper
• Exploring biomolecular recognition using optical biosensors.

  1999cites this paper
• Tranexamic Acid

  1999cites this paper
• Tranexamic acid: a review of its use in surgery and other indications.

  1999cites this paper
• The Haemostatic Balance – Astrup Revisited

  1999cites this paper
• Hereditary Defects in Fibrinolysis Associated with Thrombosis

  1999cites this paper
• Tissue factor regulates plasminogen binding and activation.

  1998cites this paper
• Hemostatic drugs.

  1998cites this paper
• Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis

  1998cites this paper
• Tissue Factor Regulates Plasminogen Binding and Activation

  1998cites this paper
• Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis.

  1998cites this paper
• Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid

  1998cites this paper
• Thrombolytic agents - An updated overview

  1998cites this paper
• Glycosylation at Asn‐289 facilitates the ligand‐induced conformational changes of human Glu‐plasminogen

  1997cites this paper
• Enhancement of Plasminogen Binding to U937 Cells and Fibrin by Complestatin

  1997cites this paper
• A monoclonal antibody directed against an epitope in the NH2-terminal region of native human plasminogen induces a modification of its functional properties

  1997cites this paper
• Production and Characterization of Recombinant Human Plasminogen(S741C-Fluorescein)

  1997cites this paper
• High‐level secretion in Pichia pastoris and biochemical characterization of the recombinantkringle 2 domain of tissue‐type plasminogen activator

  1997cites this paper
• Factor XIIa activation of plasminogen is enhanced by contact activating surfaces and Zn2+.

  1997cites this paper
• Studies on the effect of human lys-plasminogen in a rat model of global cerebral ischemia.

  1997cites this paper
• Rearrangements of the Fibrin Network and Spatial Distribution of Fibrinolytic Components during Plasma Clot Lysis

  1996cites this paper
• Fibrinogen and fibrin – proteins with complex roles in hemostasis and thrombosis

  1996cites this paper
• Thrombolytic agents--an overview.

  1996cites this paper
• Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.

  1996cites this paper
• Pharmacological manipulation of gastric juice: thrombelastographic assessment and implications for treatment of gastrointestinal haemorrhage.

  1995cites this paper
• Superficial accumulation of plasminogen during plasma clot lysis.

  1995cites this paper
• Identification of Two Functionally Distinct Lysine-binding Sites in Kringle 37 and in Kringles 3236 of Human Apolipoprotein(a) (*)

  1995cites this paper
• Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.

  1995cites this paper
• Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial.

  1995cites this paper
• Effect of fucoidan during activation of human plasminogen.

  1995cites this paper
• Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein.

  1995cites this paper
• Complement component C7 is a plasminogen-binding protein.

  1995cites this paper
• KALP AMELİYATLARINDA POSTOPERATİF KANAMANIN AZALTILMASINDA «TRANEXAMIC ACID» KULLANIMI

  1994cites this paper
• Inhibition of plasminogen activation by polymerized ampicillin.

  1994cites this paper
• Conformations and stabilities of human Glu1- and Lys78-plasminogen and of the fragments mini- and microplasminogen, analysed by circular dichroism and differential scanning calorimetry.

  1994cites this paper
• Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor.

  1994cites this paper
• [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].

  1994cites this paper
• The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.

  1994cites this paper
• Lys- and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation.

  1994cites this paper
• Role of the strictly conserved tryptophan-25 residue in the stabilization of the structure and in the ligand binding properties of the kringle 2 domain of tissue-type plasminogen activator.

  1994cites this paper
• Involvement of tyrosine-76 of the kringle 2 domain of tissue-type plasminogen activator in its thermal stability and its omega-amino acid ligand binding site.

  1994cites this paper
• Specific anionic residues of the recombinant kringle 2 domain of tissue-type plasminogen activator that are responsible for stabilization of its interaction with omega-amino acid ligands.

  1993cites this paper
• Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1.

  1993cites this paper
• Plasminogen Depletion during Streptokinase Treatment or Two-Chain Urokinase Incubation Correlates with Decreased Clot Lysability Ex Vivo and In Vitro

  1993cites this paper
• Amino acids of the recombinant kringle 1 domain of human plasminogen that stabilize its interaction with omega-amino acids.

  1993cites this paper